These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 1540406)

  • 41. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
    Drenser KA; Timmers AM; Hauswirth WW; Lewin AS
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):681-9. PubMed ID: 9538873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in the development of ribozymes and antisense oligodeoxynucleotides as antiviral agents for human papillomaviruses.
    Alvarez-Salas LM; Benítez-Hess ML; DiPaolo JA
    Antivir Ther; 2003 Aug; 8(4):265-78. PubMed ID: 14518695
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ribozymes as antiviral agents.
    Bartolomé J; Castillo I; Carreño V
    Minerva Med; 2004 Feb; 95(1):11-24. PubMed ID: 15041923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drugs made of RNA: development and application of engineered RNAs for gene therapy.
    Drude I; Dombos V; Vauléon S; Müller S
    Mini Rev Med Chem; 2007 Sep; 7(9):912-31. PubMed ID: 17897081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme.
    Unwalla H; Chakraborti S; Sood V; Gupta N; Banerjea AC
    Antiviral Res; 2006 Nov; 72(2):134-44. PubMed ID: 16790281
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-function relationship of hammerhead ribozymes as probed by 2'-modifications.
    Pieken WA; Olsen DB; Aurup H; Williams DM; Heidenreich O; Benseler F; Eckstein F
    Nucleic Acids Symp Ser; 1991; (24):51-3. PubMed ID: 1841379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of HIV-1 gp41 expression with hammerhead ribozymes.
    Fedoruk-Wyszomirska A; Szymański M; Głodowicz P; Gabryelska M; Wyszko E; Estrin WJ; Barciszewski J
    Biochem J; 2015 Oct; 471(1):53-66. PubMed ID: 26209679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The potential of ribozymes as antiviral agents.
    Sczakiel G; Nedbal W
    Trends Microbiol; 1995 Jun; 3(6):213-7. PubMed ID: 7648028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-gene therapy: the use of ribozymes to inhibit gene function.
    Couture LA; Stinchcomb DT
    Trends Genet; 1996 Dec; 12(12):510-5. PubMed ID: 9257533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic applications of group I intron-based trans-splicing ribozymes.
    Lee CH; Han SR; Lee SW
    Wiley Interdiscip Rev RNA; 2018 May; 9(3):e1466. PubMed ID: 29383855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A rapid and efficient system for screening HIV-1 Pol mRNA-specific ribozymes.
    Ramezani A; Marhin W; Weerasinghe M; Joshi S
    Can J Microbiol; 1997 Jan; 43(1):92-6. PubMed ID: 9057298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intracellular ribozyme applications.
    Castanotto D; Li JR; Michienzi A; Langlois MA; Lee NS; Puymirat J; Rossi JJ
    Biochem Soc Trans; 2002 Nov; 30(Pt 6):1140-5. PubMed ID: 12440991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Application of preformed hammerhead ribozymes in the gene therapy of cancer (review).
    Sioud M
    Int J Mol Med; 1999 Apr; 3(4):381-4. PubMed ID: 10085409
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of HIV-1 replication by ribozymes that show poor activity in vitro.
    Crisell P; Thompson S; James W
    Nucleic Acids Res; 1993 Nov; 21(22):5251-5. PubMed ID: 8255782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and anti-HIV activity of thiocholesteryl-coupled phosphodiester antisense oligonucleotides incorporated into immunoliposomes.
    Zelphati O; Wagner E; Leserman L
    Antiviral Res; 1994 Sep; 25(1):13-25. PubMed ID: 7811058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of HIV-1 replication and dimerization interference by dual inhibitory RNAs.
    Sánchez-Luque FJ; Reyes-Darias JA; Puerta-Fernández E; Berzal-Herranz A
    Molecules; 2010 Jul; 15(7):4757-72. PubMed ID: 20657391
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ribozyme- and deoxyribozyme-strategies for medical applications.
    Schubert S; Kurreck J
    Curr Drug Targets; 2004 Nov; 5(8):667-81. PubMed ID: 15578948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two tales of Annexin A2 knock-down: One of compensatory effects by antisense RNA and another of a highly active hairpin ribozyme.
    Aareskjold E; Grindheim AK; Hollås H; Goris M; Lillehaug JR; Vedeler A
    Biochem Pharmacol; 2019 Aug; 166():253-263. PubMed ID: 31158338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes.
    Konopka K; Rossi JJ; Swiderski P; Slepushkin VA; Düzgüneş N
    Biochim Biophys Acta; 1998 Jun; 1372(1):55-68. PubMed ID: 9651480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic antisense and ribozymes.
    Rossi JJ
    Br Med Bull; 1995 Jan; 51(1):217-25. PubMed ID: 7767645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.